CASRAI Dictionary

Tag: ukri funding changes

  • UK Research Funding Volatility 2026: Key Signals

    UK research funding volatility 2026 refers to the disruption research offices are managing this year as UK Research and Innovation (UKRI) replaces its council-by-council allocation model with a new three-part “buckets” structure, pauses several applicant-led grant routes, and holds discretionary research funding flat in cash terms while overall spending rises. For research administrators, the practical effect is a period of scheme-by-scheme uncertainty layered on top of institutional financial strain.

    Research funding volatility, in this context, is the combination of budget reallocation, temporary application pauses, and system migration that makes it harder for a research office to predict which schemes will be open, on what terms, and on what platform, in any given month of 2026.

    Contents

    Why Is UK Research Funding Volatile in 2026?

    UK research funding volatility in 2026 stems from three overlapping pressures hitting research offices simultaneously. UKRI is mid-way through a multi-year restructuring of how it allocates money between now and 2030. Several research councils have paused or reopened applicant-led grant routes within months of each other. And university finances are already stretched, so any funder-side disruption lands on institutions with little slack to absorb it.

    The Russell Group reports that 45% of English higher education providers are forecasting a deficit for the 2025/26 financial year, with universities in Wales, Scotland and Northern Ireland facing even more acute pressure. Against that backdrop, a paused grant call or a delayed platform migration is not a minor administrative inconvenience — it is a cash-flow and workforce-planning risk for the office managing it.

    How Is UKRI Restructuring Its Funding Model?

    From April 2026, UKRI has organised its budget into three funding “buckets”: curiosity-driven research, strategic government and societal priorities, and support for innovative companies. This replaces the previous council-led allocation logic with a cross-cutting structure intended to make funding priorities more explicit and outcome-focused.

    UKRI’s own December 2025 budget-allocations explainer confirms that the organisation’s total research and innovation budget is on a path to rise towards £10 billion a year by 2030, even as the mix shifts. Sector analysis published by Wonkhe on the CEO’s budget mapping, and coverage by the Institute of Physics, both describe discretionary curiosity-driven funding as held flat in cash terms over the same period — a real-terms reduction once inflation is applied, even as strategic-priority and innovation-linked funding lines grow.

    • Curiosity-driven research: open, investigator-led schemes; budget held broadly flat in cash terms into the near future.
    • Strategic priorities: government- and society-aligned mission funding, expected to absorb a growing share of the uplift.
    • Innovative companies: commercialisation and translation funding routed largely through Innovate UK.

    UKRI’s Chief Executive, Professor Sir Ian Chapman, confirmed to the House of Commons Science, Innovation and Technology Committee in March 2026 that the organisation will publish a new single delivery plan for the 2026/27 financial year, intended to give the sector its first detailed, comparable view of spending under the new bucket model.

    Which Funding Pauses and Cuts Have Hit Research Offices?

    Alongside the structural changes, individual councils have paused or reduced specific routes. According to analysis by the Campaign for Science and Engineering (CaSE), published in February 2026, three research councils — the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC) — paused applicant-led grant routes in the same period, while the Science and Technology Facilities Council (STFC) began cost reductions driven by rising international subscription costs.

    UKRI’s own “Pauses to funding opportunities” tracking page, last updated in June 2026, confirms that BBSRC’s applicant-led routes were paused while the council moved to an “always open” application model, and that the affected opportunities have since reopened. The table below summarises the position reported across these sources.

    Council / route 2026 development Reported driver
    MRC — applicant-led grants Paused, then phased reopening Transition to new UKRI funding model
    BBSRC — applicant-led grants Paused, reopened by mid-2026 Move to an “always open” application system
    EPSRC — selected routes Paused for review Alignment with the three-bucket structure
    STFC — facilities & subscriptions Cost reductions, some projects shelved Rising international subscription costs

    For research offices, the operational consequence is that a scheme’s status cannot be assumed stable from one funding round to the next. Pre-award teams need to check live status on each council’s page rather than relying on a static internal calendar.

    What Should Research Offices Do to Prepare?

    ARMA — the UK’s professional association for research leadership, management and administration, with member representation from across the higher education and broader research sector — has used its Spring 2026 news round-ups to flag exactly this combination of themes: funding volatility, UKRI’s restructuring, and the practical burden falling on institutional research offices. Read together, the signals point to a small number of concrete readiness actions.

    • Track pause and reopening status directly on funder pages rather than relying on cached internal deadline lists, given how quickly routes have reopened or shifted in 2026.
    • Build strategic-alignment framing into proposal support, since a larger share of new funding is routed through the strategic-priorities and innovation buckets rather than open curiosity-driven calls.
    • Plan for a hybrid systems period as UKRI continues migrating applications from its legacy Joint Electronic Submission (Je-S) system to the newer UKRI Funding Service, with some schemes on each platform simultaneously.
    • Prepare for tighter data and identifier requirements, including consistent use of ORCID iDs, as UKRI’s funding service standardises applicant and organisation data.
    • Model cash-flow scenarios against institutional deficit risk, given the Russell Group’s finding that close to half of English providers are already forecasting a 2025/26 deficit.

    None of this requires guessing at UKRI’s intentions. UKRI has published its own budget-allocation explainer and a live pauses-tracking page, and has committed to a single delivery plan for 2026/27 — the readiness task for research offices is to build monitoring habits around those existing, funder-published sources rather than waiting for a single announcement.

    Answer-First Q&A For Research Administrators

    What Is the Role of a Research Administrator in This Transition?

    A research administrator prepares and submits grant applications, tracks budgets, ensures compliance with funder terms, and manages awards through their lifecycle. During UKRI’s 2026 restructuring, that role expands to include monitoring live pause/reopening status across councils and translating shifting funding buckets into realistic advice for principal investigators.

    What Skills Do Research Administrators Need Now?

    Beyond core pre- and post-award skills, 2026 places a premium on funder-monitoring discipline, strategic framing of proposals against national priorities, and comfort operating two parallel application systems at once. Research offices report that data-governance literacy — particularly around ORCID and standardised identifiers — is becoming a distinct, named competency rather than a background task.

    What Is UKRI’s New Funding Service?

    The UKRI Funding Service is the platform UKRI is migrating applicants to from its legacy Je-S system, intended to standardise and simplify submissions across councils. Through 2026 the two systems run in parallel, so research offices must confirm on a scheme-by-scheme basis which platform a given call uses before advising applicants.

    When Will UKRI Publish Its Next Delivery Plan?

    UKRI’s Chief Executive confirmed to Parliament’s Science, Innovation and Technology Committee in March 2026 that a single delivery plan covering the 2026/27 financial year is in preparation. This is expected to give the sector its first detailed, comparable breakdown of spending under the new three-bucket model.

    What This Means for the Sector Going Forward

    The direction of travel is toward a more strategically aligned, outcome-focused UKRI, not a shrinking one — the headline budget is rising even as its composition changes. That distinction matters for research offices: the volatility is concentrated in which routes are open and on what terms, not in an overall retreat from UK research funding.

    Institutions that treat 2026 as a year of active funder-monitoring, rather than a wait for stability to return, are better placed to advise researchers accurately. Research offices that build the habit of checking UKRI’s published pauses tracker and budget explainer directly, and that read ARMA’s sector round-ups for cross-institutional context, will be positioned to respond as the 2026/27 delivery plan clarifies the practical detail behind the bucket model.

  • MRC Funding Update UKRI: Grants Reopened

    MRC funding update, in brief: the Medical Research Council paused several applicant-led grant schemes from February 2026 while UK Research and Innovation restructured to an “always open” application model; research grants, new investigator grants and partnership grants reopened on 7 April 2026, experimental medicine opportunities reopened on 30 April 2026, and MRC Proof of Concept and Impact Acceleration Awards are scheduled to reopen in July 2026. For grant holders, the practical implications are a new rolling submission window, a consolidated review structure, and firm caps on how many applications one person can lead at once.

    The MRC funding update ukri has published since February 2026 marks the most significant procedural change to Medical Research Council grant administration in over a decade. Medical Research Council (MRC) is one of UK Research and Innovation’s seven disciplinary councils, responsible for funding biomedical and health research across the UK’s higher education and institute sector. This briefing sets out exactly what changed, what remains open, and what research administrators and principal investigators need to do differently when planning 2026 applications.

    What actually changed in the MRC funding update

    On 1 February 2026, UKRI Chief Executive Ian Chapman issued an open letter to the research and innovation community announcing a new investment approach for the 2026–2030 spending review period. The letter described a shift toward a “more strategic, UKRI-wide model” for funding decisions, and confirmed that MRC would use the transition to refresh its approach to applicant-led funding.

    The headline structural change is a move to an “always open” responsive-mode system, replacing fixed application deadlines. UKRI states that published deadlines “cause significant variation in the volume of applications we receive and in reviewer availability,” and that removing them smooths these peaks and troughs. This is an operating-model change, not a funding cut — MRC says curiosity-driven research remains a committed priority, underpinned by a UKRI-wide 50% budget commitment to that category of research.

    To implement the “always open” system, MRC had to pause several applicant-led funding opportunities from February 2026 while the assessment infrastructure was rebuilt. Awards that had already been offered, accepted or started were explicitly unaffected throughout the transition.

    Reopening timeline: what’s open now and what’s still paused

    As of the most recent UKRI update (15 June 2026), most MRC applicant-led schemes have reopened. Grant holders should treat the table below as the operative reference, not the earlier February pause notice, which is now superseded.

    MRC funding opportunity Status Reopening date
    Applicant-led research grants Open 7 April 2026
    New investigator research grants Open 7 April 2026
    Partnership grants (applicant-led) Open 7 April 2026
    Experimental medicine opportunities Open 30 April 2026
    MRC Proof of Concept (formerly Developmental Pathway Funding Scheme, stage one) Reopening July 2026
    MRC Impact Acceleration Awards (formerly MRC Gap Fund) Reopening July 2026
    Fellowships, studentships, Centres of Research Excellence Never paused Continuously open

    UKRI expects the wider transition to be complete by the start of the 2027–2028 financial year (6 April 2027 to 5 April 2028). Institutions running internal peer-review or costing pipelines timed to the old deadline calendar should recalibrate now: under “always open” mode, there is no annual cycle to plan around.

    The new College of Experts review structure

    MRC’s four disciplinary research boards — covering infections and immunity, molecular and cellular medicine, neurosciences and mental health, and population and systems medicine — have been consolidated into a single College of Experts. Funding panels are now drawn flexibly from this combined pool rather than fixed to a single board.

    This restructuring supports cross-disciplinary applications that previously sat awkwardly between boards, and enables faster decisions by decoupling panel composition from a rigid quarterly schedule. Applications closed before the transition — including the legacy boards’ November 2025 round and Developmental Pathway Funding Scheme stage two — are still assessed under the old structure, with decisions expected in April 2026; MRC has confirmed a reduced number of awards from that backlog, reflecting the changeover rather than any change in typical grant size going forward.

    Application caps and resubmission rules grant holders must know

    Two new eligibility mechanics apply under the “always open” model and directly affect how principal investigators should sequence their applications:

    • Application cap: a maximum of two applications as project lead may be submitted across applicant-led responsive-mode funding calls within any rolling 12-month period.
    • Resubmission bar: an application previously unsuccessful with MRC — or with any other funder — will not be considered again for 12 months, unless MRC has explicitly invited a resubmission.
    • Cost basis unchanged: MRC continues to fund 80% of the full economic cost (FEC), with grant durations ranging from 18 months to five years and no fixed cap on requested amount, provided the sum is proportionate to project scope.

    For research offices, “always open” does not mean unlimited throughput per investigator — it shifts the constraint from a calendar deadline to a rolling personal quota. Grant-writing capacity planning built around a fixed autumn or spring deadline now needs continuous tracking of each investigator’s rolling 12-month application count.

    Budget signals: what the wider UKRI settlement means

    UKRI has stated that its overall research and innovation budget is rising across the 2026–2030 spending review period, and that the budget for biomedical and health research specifically is “in an excellent position.” Independent analysis from the Campaign for Science and Engineering notes that the overall UKRI budget is set to rise toward £10 billion a year by 2030, though how that funding is distributed across councils and themes is shifting considerably as part of the same restructuring.

    A parallel strand channels additional funding through the UKRI Life Sciences Priority Programme — a cross-council theme through which MRC accesses coordinated funding beyond its standalone curiosity-driven allocation. UKRI frames this as additive: fellowships, studentships and Centres of Research Excellence funding was unaffected throughout, and the pause applied only to specific applicant-led schemes during infrastructure changes.

    BBSRC underwent the same “always open” transition in parallel; its new investigator award and standard research grant have also reopened. Grant holders working across MRC and BBSRC funding lines should expect the same rolling-quota and resubmission mechanics on both councils, since the operating model is shared across the UKRI-wide transition rather than council-specific.

    Frequently asked questions

    Why did MRC pause its funding opportunities in 2026?

    MRC paused several applicant-led schemes from February 2026 to implement UKRI’s move to an “always open” application system. UKRI stated that fixed deadlines caused uneven application volumes and reviewer availability problems, and that removing them required behind-the-scenes changes to assessment infrastructure before reopening.

    Which MRC grants have reopened?

    Applicant-led research grants, new investigator research grants and partnership grants reopened on 7 April 2026, and experimental medicine opportunities reopened on 30 April 2026. MRC Proof of Concept and MRC Impact Acceleration Awards are scheduled to reopen in July 2026.

    Were MRC fellowships and studentships affected?

    No. MRC has confirmed that funding for fellowships, studentships, and MRC Centres of Research Excellence was not affected by the 2026 pause and remained continuously open for applications throughout the transition period.

    How many MRC applications can one person lead at once?

    Under the new rules, a principal investigator may lead a maximum of two applications across applicant-led responsive-mode funding calls within any rolling 12-month period, and unsuccessful applications face a 12-month resubmission bar unless MRC has invited one.

    Implications for institutions and grant holders

    Research offices should update three things now. First, replace deadline-driven internal sign-off calendars with continuous submission tracking, since “always open” removes the predictable peaks institutions have historically planned costing and QA cycles around. Second, build a per-investigator rolling application count into grants-management systems to enforce the two-applications-per-12-months cap before a proposal reaches MRC and is rejected on eligibility grounds. Third, brief investigators explicitly on the 12-month resubmission bar — a previously unsuccessful proposal, even a strong one, is not eligible for quick resubmission without an explicit MRC invitation, which changes revision strategy considerably.

    MRC has said it will continue to share updates and reopen remaining funding opportunities as they become ready, with full transition to the new model expected by April 2027. Institutions with active or upcoming submissions should monitor the MRC application timeline directly rather than relying on the February 2026 pause notice, which the June 2026 update has substantially superseded.